semaglutide tablets patent expiry launch date The upcoming of the in India in mid-March 2026 is What is the patent landscape

Don't Let Small Questions Slow Down Your Weight Loss Journey Questions like: Why is my Ozempic pen still not empty

6B, Figs

This risk has only been observed in animal studies

Whilst the market is currently led by Novo Nordisks semaglutide (Ozempic/Wegovy) and Eli Lillys tirzepatide (Mounjaro/Zepbound), stronger competition is expected as new entrants including Boehringer Ingelheim, Amgen, Pfizer and Roche offer novel mechanisms (dual agonists, triple agonists and amylins), formulations (oral vs injectable) and dosing regimens (daily vs weekly vs monthly)

In healthy individuals, GIP accounts for approximately 60-70% of the total incretin effect on insulin secretion, while GLP-1 contributes 30-40%

Fatigue and energy levels Fatigue is a common complaint across all three medications, particularly during the early titration weeks